Advertisement
Singapore markets open in 4 hours 44 minutes

  • Straits Times Index

    3,289.42
    -23.93 (-0.72%)
     

  • S&P 500

    5,308.15
    +61.47 (+1.17%)
     

  • Dow

    39,908.00
    +349.89 (+0.88%)
     

  • Nasdaq

    16,742.39
    +231.21 (+1.40%)
     

  • Bitcoin USD

    65,872.45
    +4,270.54 (+6.93%)
     

  • CMC Crypto 200

    1,392.79
    +124.84 (+9.86%)
     

  • FTSE 100

    8,445.80
    +17.67 (+0.21%)
     

  • Gold

    2,391.70
    +31.80 (+1.35%)
     

  • Crude Oil

    78.88
    +0.86 (+1.10%)
     

  • 10-Yr Bond

    4.3560
    -0.0890 (-2.00%)
     

  • Nikkei

    38,385.73
    +29.67 (+0.08%)
     

  • Hang Seng

    19,073.71
    -41.35 (-0.22%)
     

  • FTSE Bursa Malaysia

    1,603.23
    -2.65 (-0.17%)
     

  • Jakarta Composite Index

    7,179.83
    -7,083.76 (-49.66%)
     

  • PSE Index

    6,558.63
    -49.73 (-0.75%)
     

ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

ACELYRIN, INC.
·1-min read
ACELYRIN, INC.
ACELYRIN, INC.

LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, May 13, 2024 at 4:30 p.m. ET to discuss its first quarter 2024 financial results and provide a corporate update.

A live webcast of the conference call will be available on the Company’s website under Events & Presentations. A replay of the webcast will be available on the Company’s website for 90 days.

About ACELYRIN, INC.
ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN has two programs in late-stage clinical development. Izokibep is a next generation inhibitor of IL-17A in Phase 3 development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED.

ADVERTISEMENT

For more information about ACELYRIN, visit us at www.acelyrin.com or follow us on LinkedIn and X.

Forward Looking Statements
Some statements in this press release are, or may be considered, forward-looking statements, including statements regarding ACELYRIN’s progress, business plans and clinical trials, as well as the potential future benefits of our product candidates. While ACELYRIN, INC. considers any projections to be based on reasonable assumptions, these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated in such forward-looking statements.

ACELYRIN Contacts:
investors@acelyrin.com
media@acelyrin.com